title: Dressings and topical agents for arterial leg ulcers.
abstract: BACKGROUND
  It is estimated that people in industrialised countries have a 1% chance of suffering from a leg ulcer at some time in their life. The majority of leg ulcers are associated with circulation problems; poor blood return in the veins causes venous ulcers (around 70% of ulcers) and poor blood supply to the legs causes arterial ulcers (around 22% of ulcers). Treatment of arterial leg ulcers is directed towards correcting the poor arterial blood supply, for example by correcting arterial blockages (either surgically or pharmaceutically). If the blood supply has been restored, these arterial ulcers can heal following principles of good wound care. Dressings and topical agents make up a part of good wound care for arterial ulcers but there are many products available and it is unclear what impact these have on ulcer healing. This is an update of a review first published in 2003.
  
  
  OBJECTIVE
  To determine whether topical agents and wound dressings affect healing in arterial ulcers. To compare healing rates, patient-centred outcomes and costs between wound dressings and topical agents.
  
  
  METHODS
  For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched November 2014) and The Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library) (2014, Issue 10).
  
  
  METHODS
  Randomised controlled trials (RCTs), or controlled clinical trials (CCTs) evaluating dressings and topical agents in the treatment of arterial leg ulcers were eligible for inclusion. The participants had to have ulcers that were described as arterial, and the time to healing, proportion completely healed, or rate of reduction in ulcer area had to be reported. All wound dressings and topical agents were eligible for inclusion in this review.
  
  
  METHODS
  The two review authors independently extracted information on the participants' characteristics, the interventions, and outcomes using a standardised data extraction form. Disagreements between the review authors were resolved through discussion.
  
  
  RESULTS
  One trial met the inclusion criteria, which was a small trial that compared 2% ketanserin ointment in polyethylene glycol (PEG) with vehicle alone (PEG) control, changed twice a day in 40 participants with arterial leg ulcers. The overall quality of the evidence was low with a single small included study which showed inadequate reporting of the results and had too short a follow-up time (eight weeks) to be able to capture sufficient healing events to allow comparisons to be made. In addition, the study was of low methodological quality. The majority of the 'risk of bias' domains received an 'unclear' risk rating as very little information was provided in the text on the methods of the study. The trial demonstrated increased wound healing in the ketanserin group, compared with the control group, but the trial was too small and had too short a follow-up period (eight weeks) to be able to determine whether there was any difference in healing rates. It should also be noted that ketanserin is not licensed in all countries for use in humans.
  
  
  CONCLUSIONS
  There is insufficient evidence to determine whether the choice of topical agent or dressing affects the healing of arterial leg ulcers.
authors.affiliation: Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK, EH8 9AG.
authors.forename: Rachel
authors.initials: R
authors.lastname: Forster
authors.forename: Fania
authors.initials: F
authors.lastname: Pagnamenta
mesh_terms: D000287:Administration, Topical; D001158:Arteries; D006801:Humans; D007650:Ketanserin / Q000008:administration & dosage*; D007871:Leg Ulcer / Q000628:therapy*; D009779:Occlusive Dressings; D009824:Ointments / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011092:Polyethylene Glycols / Q000008:administration & dosage; D014945:Wound Healing
chemical_list: D009824:Ointments; D010975:Platelet Aggregation Inhibitors; D011092:Polyethylene Glycols; D007650:Ketanserin